J&J has asked the Food and Drug Administration for flexibility with its booster, arguing the extra dose adds important protection as early as two months after initial vaccination - but that it might work better if people wait until six months later.
Thursday, advisers to the Food and Drug Administration evaluated the evidence that Moderna boosters should be offered, too -- and on Friday, they’ll tackle the same question for those who got Johnson & Johnson’s vaccine.
The data strongly suggests that the delta variant wreaked havoc on the job market in August. As COVID-19 cases surged, quits jumped in restaurants and hotels and rose in other public-facing jobs, such as retail and education.
On Thursday and Friday, the Food and Drug Administration convenes its independent advisers for the first stage in the process of deciding whether extra doses of the two vaccines should be dispensed and, if so, who should get them and when. The final go-ahead is not expected for at least another week.
The government has fully approved the COVID-19 vaccine for those 16 and over but only granted an emergency authorization for anyone 12 to 15. Once federal regulators fully approve the vaccine for that group, the state will require students in seventh through 12th grades to get vaccinated in both public and private schools.
The company said it will soon ask health officials in the U.S. and around the world to authorize the pill’s use. A decision from the U.S. Food and Drug Administration could come within weeks after that, and the drug, if OK’d, could be distributed quickly soon afterward.
New guidance now says those ages 18 to 64 in high-risk professional and institutional settings and those ages 18 to 49 with underlying health conditions may get a booster dose of Pfizer at least six months after their second shot, based on their individual benefits and risks.